Skip to content

Scalpel Versus Diathermy for Transverse Abdominal Incision in First Elective Caesarean Section

Scalpel Versus Diathermy for Transverse Abdominal Incision in Women Undergoing First Elective Caesarean Section: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05905861
Enrollment
84
Registered
2023-06-15
Start date
2023-07-31
Completion date
2024-12-31
Last updated
2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section, Intraoperative Blood Loss, Postoperative Pain, Wound Heal

Brief summary

The objective of this study will be to compare two methods of skin incisions during the first caesarean section (CS), that is scalpel and diathermy, assessing differences in blood loss during incision, incisional time, total surgery time, post-operative pain, wound healing, complications, and cosmetic outcomes.

Detailed description

The scalpel has been historically used as the primary cutting tool during caesarean section (CS). However, advancements in surgical devices have introduced alternatives, such as the option to make a diathermic cut using electrosurgical units. General surgeons have extensively demonstrated the advantages of diathermy over the scalpel for abdominal wall incisions, including faster opening time, reduced incisional blood loss, decreased post-operative pain, and a comparable wound complication rate. In obstetrics, there is a scarcity of evidence in this regard, and no consensus or guidelines have been established regarding the optimal method for making a transverse abdominal incision during the first elective CS. Currently, the choice between using a scalpel or diathermy remains at discretion of the obstetric surgeon. The objective of this study will be to compare both methods of skin incisions during the first CS, assessing differences in blood loss during incision, incisional time, total surgery time, post-operative pain, wound healing, complications, and cosmetic outcomes.

Interventions

PROCEDURESkin incision with scalpel.

A Pfannenstiel skin incision will be performed using a scalpel, extending through the subcutaneous tissue and rectus sheath. After separation of rectus muscles, peritoneum will be visualized and opened. Optimal hemostasis will be achieved by applying pressure to skin blood vessels and ligating any subcutaneous bleeding. Group A: skin incision with a scalpel.

PROCEDURESkin incision with a diathermy.

A Pfannenstiel skin incision will be made using a scalpel. Subsequently, a diathermy pen electrode will be employed for the dissection of deeper tissues. Optimal hemostasis will be achieved by using the same blade pen electrode, set to coagulation mode. Group B: skin incision with diathermy.

Sponsors

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Women without a history of previous cesarean section or other abdominal surgery 2. Age greater then 18 years (only adult patients) 3. Body Mass Index (BMI) between 18.5 and 29.9 kg/m2 4. Gestational age greater then 37 weeks (at term pregnancies) 5. No contraindications to spinal anesthesia 6. Indication to elective CS: extra-obstetrical reasons, failure of medical induction of labor, breech fetal presentation 7. Informed consent

Exclusion criteria

1. Women refusing to participate in the study 2. Women undergoing urgency or emergency cesarean deliveries 3. Women with a history of previous cesarean section or abdominal surgery 4. Women with multifetal pregnancies 5. Necessity of general anesthesia 6. Use of anticoagulants 7. Patients needing a median longitudinal abdominal section 8. Patients with pacemakers 9. Allergy to cephalosporins 10. Any medical disorder that can affect wound healing as diabetes, hypertension, hepatic or renal diseases, chronic anemia, chronic skin conditions, congenital or acquired bleeding diathesis.

Design outcomes

Primary

MeasureTime frameDescription
Incision blood lossDuring surgeryThis will be calculated by weighing the gauze pre and postoperatively (1mg = 1ml) after complete hemostasis will be achieved.

Secondary

MeasureTime frameDescription
Incision timeDuring surgeryWe will compare incisional time by using a digital clock. The incisional time will be established as follows: when skin incision will be made, the surgeon will verbally announce start . Once the parietal peritoneum will be opened, the surgeon will announce stop. The incision time will be calculated as the difference between start and stop times.
Total surgery timeDuring surgeryTotal surgery time will be the time between the start of the skin incision and the completion of the skin suture.
Post-operative pain assessed by VASDuring the first three days after surgeryPost-operative pain will be evaluated for each participant at 1, 4, 8, 16, 24, 48, 72 hours postoperatively, by using the Visual Analog Scale (VAS). The VAS consists of a 10 cm long horizontal line with its extremes marked as 'no pain' (0) and 'worst pain imaginable' (10).
Wound complicationsDuring the first month after surgeryWill include edema, seroma, hematoma, dehiscence, and infection. The wound will be evaluated 24h and 72h after surgery, before patients discharge. Then, outpatient wound evaluation will be made 7 and 30 days after surgery.
Cosmetic wound evaluation assessed by POSASOne month after surgeryThe cosmetic aspect of the wound will be evaluated outpatient 30 days after surgery by using the Patient and Observer Scar Assessment Scale (POSAS), that is a questionnaire that was developed to assess scar quality. It consists of two separate six-item scales (Observer Scale and Patient Scale), both of which are scored on a 10-point rating scale (1 = best result; 10 = worst result).

Countries

Italy

Contacts

Primary ContactAmerigo Vitagliano, MD, PhD
amerigo.vitagliano@gmail.com0805593321
Backup ContactAmerigo Vitagliano
amerigo.vitagliano@gmail.com0805593321

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026